Breaking the speed limit: Fast, high-resolution peptide and tryptic digest separations using fused-core particles Stephanie Schuster 1, Barry Boyes 1,2, and Darryl Johnson 2 1 Advanced Materials Technology, Wilmington, DE 2 Complex Carbohydrate Research Center, University of Georgia, Athens, GA
Outline Problem: slow speed of biomolecule separations Prior attempt to address A better solution Brief history of superficially porous particles in HPLC Development and characterization of 16 Å fused-core particles Particle size distribution Pore size distribution Stability Efficiency Applications using HALO Peptide ES-C18 LC/MS of tryptic digests Peak capacity Conclusions and summary
Problem: Slow Speed of Biomolecule Separations Higher molecular weight has mass transfer limitations (diffusion) Complex: long shallow gradients used for increasing resolution of heterogeneous mixtures of similar structures (peptides and their PTMs) Less complex: not as difficult to resolve, but many samples to screen; need high throughput method Example: one main peptide with minor components that MUST be quantified Not all possible structures may be known (isobaric?)
Prior Attempt to Address Problem N.D. Danielson and J.J. Kirkland, Anal. Chem.1987, 59, 251-256. 1-2-µm silica particles Bonded with C4 Not Ideal Inefficient (h = 3.5) Unstable with repeated use of TFA-containing mobile phases (surface chemistry) Required high pressure solvent delivery capability to provide necessary efficiency Required special attention to extra column effects (band dispersion) Required smaller frits Increased chance that particulates in the sample / mobile phase will clog the frits must filter both sample & mobile phase
A Better Solution Use superficially porous particles Advantages Low back pressure due to the particle design (solid core with a porous shell) No need for specialized HPLC equipment Not necessary to filter samples and mobile phase since frits are not as small as needed for sub-2-µm High resolution is maintained at high flow rates (flat C-term in van Deemter plot)
History of Superficially Porous Particles Superficially porous particles first used in GC by Golay 1967: Horvath, Preiss, and Lipsky described separation using ~5 µm cores with an anion exchange resin; called pellicular a skin-like coating 1969: Kirkland, Zipax ~ µm Silica sol on glass beads Mid 7 s: Kirkland, Permaphase permanently bonded stationary phase on SPP particles
History of Superficially Porous Particles Year Who Particle Name 1 Agilent Technologies 7 7 Advanced Materials Technology Supelco Sigma-Aldrich Poroshell Core (µm) Shell (µm) Total Size (µm) 4.5.25 5. HALO 1.7.5 2.7 Ascentis Express 9 Phenomenex Kinetex 1.9 1.25 Agilent Technologies 1.7.5 2.7.35.23 2.6 1.7 Poroshell 1 1.7.5 2.7
Fused-Core Particles: Varying Pore Size Porous Shell Solid Core x d p y x (µm) y (µm) d p (µm) Pore Size (Å) Surface Area (m 2 /g) 1.7.5 2.7 9 15 1.7.5 2.7 16 8
Particle Size Distributions 35 25 Number 15 Standard Halo 9 A mode = 2.8 um, SD =.14 Halo Peptide 16 A mode = 2.82 um, SD =.14 5-5 2 4 6 Particle Diameter, [µm]
Pore Size Distributions.6 dv/dlog(w) Pore Volume, [cm^3/g*a].5.4.3.2.1 Standard Halo Halo Peptide 1 Pore Width, [A]
Effect of Pore Size on Peptide and Small Protein Separations w=.516 Standard HALO C18 9 Å w=.861 w=.819 w=.5411 w=.4671 w=.491 w=.516 HALO Peptide ES-C18 16 Å w=.457 w=.837 w=.43 1 2 3 4 5 6 7 8 9 11 12 13 14 15 Time (min.) 1. Leu-enk (555 g/mol) 2. Bovine Insulin (5733 g/mol) 3. Human Insulin (588 g/mol) 4. Cytochrome C (12, g/mol) 5. Lysozyme (14, g/mol) Columns: 4.6 x mm Flow rate: 1.5 ml/min Temperature: C A:.1% TFA/% ACN, B:.1% TFA/7% ACN Gradient: 15% to 5% B in 15 min. Injection volume: 5 µl Detection: 2 nm
Effect of Pore Size on Efficiency 16 14 Reduced Plate Height, h 12 8 6 4 2 β-amyloid (1-38) MW: Da 9 Å 179% lower β-amyloid (1-38) MW: Da 16 Å Leu-Enk MW: 555 Da 16 Å 1 2 3 4 5 6 7 Mobile Phase Velocity, mm/sec Columns: 4.6 x mm HALO C18, 2.7 µm, 9 Å 4.6 x mm HALO Peptide ES-C18, 2.7 µm, 16 Å Mobile Phase: Leu-Enk: 21% ACN/79% Water/.1% TFA β-amyloid (1-38) 16 Å : 29% ACN/71% Water/.1% TFA β-amyloid (1-38) 9 Å : 27% ACN/73% Water/.1% TFA Temperature: 6 C Detection: 215 nm
9 Peptides and 2 Proteins in < 1 minute Column: HALO Peptide ES-C18, 4.6 x 5 mm; Mobile Phase: A:.1% TFA/% ACN; B:.1% TFA/7% ACN; % to 87.5% B in 1 min; Flow Rate: 5. ml/min; Temperature: 6 C; Pressure: 3 bar; LC System: Conventional HPLC, Agilent 1; mau 15 1 3 5 8 9 11 Sample: 1. Gly-Tyr 2. Val-Tyr-Val 3. Angiotensin 1/2 (1-7) amide 4. Met-enk 5. Angiotensin 1/2 (1-8) amide 6. Angiotensin II 7. Leu-enk 8. Ribonuclease A 9. Angiotensin (1-12) (human). Angiotensin (1-12) (mouse) 11. Porcine Insulin 2 4 6 7 5-5.1.2.3.4.5.6.7.8.9 min
Ultra Fast High Resolution Separation of Apo Transferrin Tryptic Digest 15 1.75 ml/min 5-6% B in min. 1 9 7 5 Abs. @ 215 nm (mau) - 5 15 25 15 1 1. ml/min 5-6% B in min. 1 9 7 5-5 Column: 2.1 x mm ES-C18 16 A A: Water/.1% TFA B: 8% ACN /.1% TFA Temp: 6 C 15 1 1 9 15 Detection: 215 nm Sample: apotransferrin tryptic digest Injection volume: 15 ul 7 1.5 ml/min 5-6% B in 15 min. 5-5 Time (min) 15
Stability Column: 2.1 x mm; Flow Rate:.5 ml/min; Temperature: 6 C A: water/.1% TFA; B: 7% ACN/% water/.1% TFA Gradient: 9-55% B in min.; Injection volume: 5 µl; Shimadzu Prominence UFLC XR Injection 775 Injection 6 Injection Injection Injection 1 2 4 6 Time (min.) 8 Sample: Gly-Tyr, Val-Tyr-Val, Met-enk, Angiotensin II, Leu-enk Ribonuclease, Porcine Insulin
Rapid Separation at High Temperature Column: 2.1 x 5 mm Halo Peptide ES-C18; Flow:.5 ml/min; A:.1% TFA; B:.1% TFA/8% ACN; Gradient: 15-5% B in 12.5 min.; Sample: 5 µl (25-5 ng) Amyloid b Peptides and Fragments Abs (2 nm) 8 7 6 5 8 7 6 5 C Ab(12-28) Ab(13-27) 2 4 6 8 12 8 C Ab(17-28) Ab(1-28) Ab(1-38) Ab(1-) Ab(1-42) Ab(17-) Ab(17-42) 2 4 6 8 12 8 7 6 5 8 7 6 5 9 C 2 4 6 8 12 7 C 2 4 6 8 12 Time (min.) Efficient separation of a difficult sample accomplished in less than 15 minutes. Note requirement for high temperature to achieve full recovery of Ab(17-42).
Low Back Pressure Permits Coupled Columns for Increased Resolution 15 1 Abs. (mau) 1 9 7 5 - Minutes 5 6 7 8 Columns: 2 @ 2.1 x mm ( mm total) Halo Peptide ES-C18; Flow rate:.5 ml/min.; Gradient: 5-65% B in 1 min.;.1% TFA; B: 8% acetonitrile/.1% TFA; Temperature: 45 oc; Injection volume: 15 μl (15 µg). 9
Typical Analysis Times for Peptide and Tryptic Digest Separations Sample Dependent Simple proteomics sample: - 45 min gradients Complex tryptic digest: 45 min - 3 hour gradients Many tens to thousands of proteins, leading to hundreds of thousands of components
High mobile phase velocity LC/MS analysis of an apomyoglobin tryptic digest Column:.2 x 5 mm Halo Peptide ES-C18; Flow rate; 9 μl/min; Gradient: 2-45% B in 15 min; A:.1% formic acid/water; B: acetonitrile/.1% formic acid; Maximum pressure: 3 bar; Sample- 3 pmol apomyoglobin digest. 95 9 85 NL: 7.11E5 Base Peak F: ITMS + c ESI Full ms [.-.] MS 9. 752.51.32 84.64 14.3 99.9 8 75 7 65 6 Relative Abundance 55 5 45 35 12.97 69.44 25 15 5 2.51 1232.73 5.15 74.42 7.65 618.97 2 4 6 8 12 14 Time (min).96 748.38 15 min.
High mobile phase velocity LC/MS analysis of mixed protein digests Column:.2 x 15 mm Halo Peptide ES-C18; Flow rate: 4 μl/min; Gradient: 2-45% B in 85 min; A:.1% formic acid/water; B: acetonitrile/.1% formic acid; Maximum pressure: 3 bar; Sample: mixed protein digest (5 pmol total of transferrin, carbonic anhydrase, and apomyoglobin). 95 9 85 8 NL: 4.86E6 Base Peak F: ITMS + c ESI Full ms [.-.] MS 6.25 1574.92 75 7 75.92 1664.47 65 6 Relative Abundance 55 5 45 35 56.25 37.46 62.46 1569.45 81. 1319.51 25 15. 9.25.1 864.39 5.73 942.26 85 min. 5 29.78 83.17 12.23 921.56 36.16 79.96 6 8 Time (min)
Ammonium formate as an additive for LC/MS separations Column:.2 x 5 mm Halo Peptide ES-C18; Flow rate: 9 μl/min; Gradient: 2-45% B in 15 min; Mobile phases as shown; Sample: 2 μl (3 pmol) apomyoglobin digest. A:.1 % Formic Acid B:.1 % Formic Acid/ mm Ammonium Formate Relative Abundance 9 8 7 6 5 NL: 8.4E5 Base Peak F: ITMS + c ESI Full ms [.-.] 2.74 1266.39 5.75 74.39 7.77 927.59 9.27 752.42.28 84.58.93 748.38 12.93 69.27 13.95 98.93 14.77 98.59 17.7 1952.54 2 4 6 8 12 14 16 18 Time (min) Relative Abundance 9 8 7 6 5 NL: 5.18E5 Base Peak F: ITMS + c ESI Full ms [.-.] 2.47 1127.67 5.33 1549.9 7.97 684. 8.42 74.49 9.56 752.35.63 84.51 11.28 748.41 13.35 69.43 14.17 99.3 16.54 943.13 19.49 1617.64 2 4 6 8 12 14 16 18 DJ_Halo_stem_ApoMyoglobin_3pmol_2_517_5171779 #1914-1933 RT: 12.23-12.33 AV: 5 NL: 5.78E4 F: ITMS + c ESI Full ms [.-.] 754.9 Relative Abundance 9 8 7 6 5 395.19 53.34 78.69 515.81 871.72 1231.28 156.56 969.89 1631.89 1831.49 1992.69 6 8 1 1 16 18 m/z DJ_Halo_stem_ApoMyoglobin_3pmol_AF_1_518 #1945-1971 RT: 12.79-12.95 AV: 11 NL: 6.88E4 F: ITMS + c ESI Full ms [.-.] 754.52 Relative Abundance 9 8 7 6 5 941.18 395.19 494.21 69.2 37. 1232.29 156.56 164.58 1833.39 1963.6 6 8 1 1 16 18 m/z
Peak Capacity Peak capacity is the maximum number of peaks that can be resolved with R s = 1 in a given chromatographic space The higher the peak capacity of a given separation, the more likely it is that the peaks will be resolved in a complex mixture Peak capacity [n pc ] calculated as t i = time of the initial measurable peak in the gradient t f = time of the final peak W 4s = average of the 4s widths of the peaks in the chromatogram 11 peptides used for the calculation of peak capacity Span a wide range of hydrophobicities to mimic an actual tryptic digest Asp-Phe, Tyr-Tyr-Tyr, angiotensin (1-7) amide, bradykinin, Leu-Enk, angiotensin II, angiotensin 1-12 (human), beta-endorphin, sauvagine, melittin, and Hel 11-7
Peak Capacity Comparisons 2.3x lower back pressure 11% lower peak capacity 75 65 HALO Peptide ES-C18 npc = 251 Pmax = 239 bar Abs. @ 215 nm 55 45 35 25 15 5-5 75 65 Time (min) 5 6 5 6 BEH C18 npc = 278 Pmax = 553 bar 55 Abs. @ 215 nm 45 35 25 15 5-5 Time (min) Columns: 2.1 x mm Halo Peptide ES-C18, 2.1 x mm BEH C18; Flow rate:.5 ml/min; Temperature 45 C; Gradient: 5-7% B in 6 min; A: water/.1% trifluoroacetic acid; B: 8/ acetonitrile/water/.1% trifluoroacetic acid; Sample: 15 μl of 11 synthetic peptides (5 ng each).
Peak Capacity Comparisons Increased column length and gradient time by 1.5x 1.57x lower back pressure 9% higher peak capacity 75 65 BEH C18 npc = 278 Pmax = 553 bar Abs. @ 215 nm 55 45 35 25 15 5-5 75 Time (min) 65 Abs. @ 215 nm 55 5 6 HALO Peptide ES-C18 npc = 3 Pmax = 352 bar 45 35 25 15 5-5 5 6 7 8 9 Time (min) Columns: 2.1 x mm BEH C18, 2.1 x 15 mm HALO Peptide ES-C18; Flow rate:.5 ml/min; Temperature 45 C; Gradient: 5-7% B in 6 or 9 min; A: water/.1% trifluoroacetic acid; B: 8/ acetonitrile/water/.1% trifluoroacetic acid; Sample: 15 μl of 11 synthetic peptides (5 ng each).
DryLab Optimization of Peak Capacity Predicted chromatogram matches well with the actual 4, 3,8 3, HALO Peptide ES-C18 (predicted) 2,8 2, 1,8 1, 8-6 8 1 1 Time(min) 35 HALO Peptide ES-C18 (actual) npc = 5 Pmax = 56 bar Abs. @ 215 nm 25 15 5-5 6 8 Time (min) 1 1 Columns: 2.1 x mm Halo Peptide ES-C18 and 2.1 x 15 mm Halo Peptide ES-C18; Flow rate:.5 ml/min; Temperature 45 C; Gradient: 5-7% B in 15 min; A: water/.1% TFA; B: 8/ acetonitrile/water/.1% trifluoroacetic acid; Sample: 15 μl of 11 synthetic peptides (5 ng each); Detection: 215 nm.
DryLab Optimization of Peak Capacity: Synthetic Peptides vs. Tryptic Digest Tryptic digest sample has ~ 6% of the peak capacity of the synthetic peptide sample Synthetic peptides HALO Peptide ES-C18 npc = 5 Pmax = 56 bar 35 Abs. @ 215 nm 25 15 5 Abs.@ 215 nm -5 35 25 15 5-5 6 Time (min)8 1 1 Apomyoglobin tryptic digest HALO Peptide ES-C18 npc = 322 Pmax = 56 bar 6 8 1 1 Time (min) Columns: 2.1 x mm Halo Peptide ES-C18 and 2.1 x 15 mm Halo Peptide ES-C18; Flow rate:.5 ml/min; Temperature 45 C; Gradient: 5-7% B in 15 min; A: water/.1% TFA; B: 8/ acetonitrile/water/.1% trifluoroacetic acid; Sample: 15 μl of 11 synthetic peptides (5 ng each), or 15 µl apomyoglobin digest (15 µg); Detection: 215 nm.
172 Peak Capacity in < 6 Minutes 135 Abs. @ 215 nm (mau) 115 95 75 55 35 HALO Peptide ES-C18 n pc = 172 P max = 548 bar 15-5 1 2 3 4 5 6 Time (min) Fast separation of 11 peptides in 6 minutes with 2.9 minimum resolution. Column: 2.1 x mm Halo Peptide ES-C18; Flow rate: 1.25 ml/min; Temperature 45 C; Gradient: - 54% B from -4 min. 54- % B from 4-6 min; A: water/.1% TFA; B: 8/ acetonitrile/water/.1% trifluoroacetic acid; Sample: 15 μl of 11 synthetic peptides, 5 ng each; Detection: 215 nm.
Conclusions and Summary Fused-core HALO Peptide provides a better solution for increasing the speed of biomolecule separations Particle size distribution remains sharp as compared to the smaller pore size fused-core particles Stability is high at low ph and elevated temperatures due to the nature of the sterically protected bonded phase Increased pore size material shows lower resistance to diffusion into the pores for larger molecules, as reflected by increased column efficiency at high mobile phase velocity Provides ultra fast, high resolution data with low back pressure High throughput methods are possible due to the faster gradients that can be employed while still maintaining high resolution separations Peak capacity is within % of sub-2-µm particle column performance, but with less than half the back pressure
Acknowledgements Advanced Materials Technology Jack Kirkland Barry Boyes Joe DeStefano Tim Langlois Brian Wagner Complex Carbohydrate Research Center Ron Orlando Financial support from NIH grant GM77688